Showing results (901-910 of 925) with videos related to
Sort By:
Pageof 93
Journal of Viral Hepatitis|October 8, 2014
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impactN K Martin, G R Foster, J Vilar, et al.Targeted Oncology|April 29, 2024
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 StudyMichael Maris, Gilles Salles, Won Seog Kim, et al.Cancer|January 18, 2017
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G Berdeja, et al.Drugs of Today (Barcelona, Spain : 1998)|May 10, 2006
Description of the ICTI consortium: an integrated approach to the study of Chlamydia trachomatis infectionS A Morré, J Spaargaren, J M Ossewaarde, et al.Journal of Hematology & Oncology|February 24, 2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.Atherosclerosis Plus|November 13, 2024
A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: Protocol for the EAS Lipid Registry of Africa (LIPRA)Ashraf Reda, Alexander R M Lyons, Alberto Zambon, et al.Journal of Hematology & Oncology|November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsMoshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.JACC. Cardiovascular Interventions|March 8, 2024
Real-World Outcomes for the Fifth-Generation Balloon Expandable Transcatheter Heart Valve in the United StatesCurtiss T Stinis, Amr E Abbas, Paul Teirstein, et al.Haematologica|January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-ISrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.Pageof 93